UroGen Pharma (URGN) Stock Forecast, Price Target & Predictions
URGN Stock Forecast
UroGen Pharma stock forecast is as follows: an average price target of $42.00 (represents a 220.61% upside from URGN’s last price of $13.10) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
URGN Price Target
The average price target for UroGen Pharma (URGN) is $42.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $22.00. This represents a potential 220.61% upside from URGN's last price of $13.10.
URGN Analyst Ratings
According to 8 Wall Street analysts, UroGen Pharma's rating consensus is 'Buy'. The analyst rating breakdown for URGN stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
UroGen Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 14, 2024 | Stephen Richardson | Evercore ISI | $46.00 | $20.26 | 127.05% | 251.15% |
| Jun 14, 2024 | Leland Gershell | Oppenheimer | $40.00 | $17.50 | 128.57% | 205.34% |
| Jun 14, 2024 | Raghuram Selvaraju | H.C. Wainwright | $60.00 | $17.50 | 242.86% | 358.02% |
| Jun 14, 2024 | Paul Choi | Goldman Sachs | $22.00 | $17.50 | 25.71% | 67.94% |
| May 14, 2024 | Leland Gershell | Oppenheimer | $32.00 | $13.07 | 144.84% | 144.27% |
| Mar 15, 2024 | Leland Gershell | Oppenheimer | $34.00 | $14.46 | 135.13% | 159.54% |
| Dec 12, 2022 | - | H.C. Wainwright | $23.00 | $7.94 | 189.67% | 75.57% |
The latest UroGen Pharma stock forecast, released on Jun 14, 2024 by Stephen Richardson from Evercore ISI, set a price target of $46.00, which represents a 127.05% increase from the stock price at the time of the forecast ($20.26), and a 251.15% increase from URGN last price ($13.10).
UroGen Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 6 |
| Avg Price Target | - | - | $39.00 |
| Last Closing Price | $13.10 | $13.10 | $13.10 |
| Upside/Downside | -100.00% | -100.00% | 197.71% |
In the current month, the average price target of UroGen Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to UroGen Pharma's last price of $13.10. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 18, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 22, 2024 | Guggenheim | - | Buy | Initialise |
| Aug 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 14, 2024 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Jun 14, 2024 | Keefe, Bruyette & Woods | - | Outperform | Upgrade |
| Jun 14, 2024 | Benchmark | Buy | Buy | Hold |
| Jun 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 14, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Jun 13, 2024 | Cowen & Co. | Buy | Buy | Hold |
UroGen Pharma's last stock rating was published by Oppenheimer on Sep 18, 2024. The company gave URGN a "Outperform" rating, the same as its previous rate.
UroGen Pharma Financial Forecast
UroGen Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $20.85M | $21.14M | $17.19M | $18.09M | $16.10M | $16.60M | $13.56M | $16.17M | $11.35M | $13.03M | $7.49M | $7.97M | $3.46M | $372.00K | - | - | $481.00K |
| Avg Forecast | $51.16M | $40.29M | $32.64M | $23.43M | $29.27M | $24.56M | $23.97M | $21.39M | $22.57M | $20.03M | $20.12M | $17.11M | $18.51M | $20.15M | $17.22M | $15.17M | $16.24M | $15.37M | $11.76M | $9.06M | $7.62M | $3.33M | $396.17K | $905.00 | $100.00K | $374.11K |
| High Forecast | $54.97M | $43.29M | $35.07M | $25.17M | $31.45M | $25.36M | $25.75M | $22.98M | $23.07M | $21.53M | $21.62M | $18.38M | $19.89M | $21.65M | $18.11M | $15.95M | $17.08M | $16.15M | $12.36M | $9.52M | $8.01M | $3.51M | $416.46K | $1.08K | $105.12K | $448.93K |
| Low Forecast | $48.22M | $37.97M | $30.77M | $22.08M | $27.59M | $23.77M | $22.59M | $20.16M | $22.06M | $18.88M | $18.97M | $16.13M | $17.45M | $18.99M | $16.58M | $14.60M | $15.63M | $14.79M | $11.32M | $8.72M | $7.34M | $3.21M | $381.27K | $723.00 | $96.24K | $299.29K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 5 | 6 | 6 | 3 | 3 | 7 | 4 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | 1.05% | 1.00% | 0.98% | 0.80% | 0.96% | 0.89% | 1.00% | 0.74% | 1.11% | 0.83% | 1.05% | 1.04% | 0.94% | - | - | 1.29% |
UroGen Pharma's average Quarter revenue forecast for Dec 23 based on 3 analysts is $22.57M, with a low forecast of $22.06M, and a high forecast of $23.07M. URGN's average Quarter revenue forecast represents a 8.23% increase compared to the company's last Quarter revenue of $20.85M (Sep 23).
UroGen Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 5 | 6 | 6 | 3 | 3 | 7 | 4 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-12.18M | $-15.38M | $-20.98M | $-19.88M | $-17.17M | $-18.11M | $-21.50M | $-27.97M | $-29.76M | $-25.47M | $-25.51M | $-26.54M | $-28.32M | $-30.87M | $-37.34M | $-21.38M | $-13.14M |
| Avg Forecast | $-48.82M | $-38.45M | $-31.15M | $-22.36M | $-27.94M | $-23.44M | $-22.87M | $-20.41M | $-21.54M | $-19.12M | $-19.20M | $-16.33M | $-17.67M | $-31.21M | $-16.44M | $-29.00 | $-15.50M | $-14.66M | $-11.22M | $-27.88M | $-7.27M | $-3.18M | $-378.08K | $-34.11M | $-22.96M | $-10.22M |
| High Forecast | $-46.02M | $-36.24M | $-29.36M | $-21.08M | $-26.33M | $-22.69M | $-21.56M | $-19.24M | $-21.06M | $-18.02M | $-18.10M | $-15.39M | $-16.65M | $-24.97M | $-15.82M | $-23.00 | $-14.92M | $-14.11M | $-10.80M | $-22.30M | $-7.00M | $-3.06M | $-363.87K | $-27.29M | $-18.37M | $-8.18M |
| Low Forecast | $-52.46M | $-41.31M | $-33.47M | $-24.02M | $-30.02M | $-24.20M | $-24.58M | $-21.93M | $-22.02M | $-20.54M | $-20.63M | $-17.55M | $-18.98M | $-37.45M | $-17.28M | $-35.00 | $-16.30M | $-15.42M | $-11.80M | $-33.46M | $-7.65M | $-3.35M | $-397.44K | $-40.93M | $-27.55M | $-12.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.64% | 0.80% | 1.28% | 1.13% | 0.55% | 1.10% | 741482.76% | 1.80% | 2.03% | 2.27% | 0.91% | 3.65% | 8.90% | 81.66% | 1.09% | 0.93% | 1.29% |
undefined analysts predict URGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than UroGen Pharma's previous annual EBITDA (undefined) of $NaN.
UroGen Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 5 | 6 | 6 | 3 | 3 | 7 | 4 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | $-21.88M | $-24.14M | $-30.21M | $-28.25M | $-25.83M | $-26.69M | $-28.39M | $-28.45M | $-30.21M | $-26.22M | $-25.93M | $-30.53M | $-28.82M | $-31.35M | $-37.79M | $-21.44M | $-13.38M |
| Avg Forecast | $-18.89M | $-25.99M | $-29.94M | $-34.96M | $-28.78M | $-30.45M | $-30.64M | $-31.91M | $-25.04M | $-31.15M | $-41.83M | $-48.97M | $-39.52M | $-31.69M | $-46.95M | $-30.00 | $-43.27M | $-47.13M | $-41.79M | $-28.35M | $-50.49M | $-55.05M | $-58.55M | $-33.83M | $-22.01M | $-10.41M |
| High Forecast | $-17.48M | $-24.05M | $-27.71M | $-32.35M | $-26.64M | $-29.00M | $-28.35M | $-29.53M | $-22.80M | $-28.83M | $-38.71M | $-45.32M | $-36.57M | $-25.35M | $-44.65M | $-24.00 | $-41.15M | $-44.83M | $-39.75M | $-22.68M | $-48.02M | $-52.36M | $-55.69M | $-27.06M | $-17.61M | $-8.33M |
| Low Forecast | $-20.72M | $-28.51M | $-32.84M | $-38.35M | $-31.57M | $-32.99M | $-33.60M | $-35.00M | $-26.16M | $-34.17M | $-45.88M | $-53.72M | $-43.35M | $-38.02M | $-50.07M | $-36.00 | $-46.15M | $-50.27M | $-44.58M | $-34.02M | $-53.85M | $-58.71M | $-62.45M | $-40.59M | $-26.41M | $-12.49M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.70% | 0.58% | 0.62% | 0.71% | 0.82% | 0.57% | 946400.00% | 0.66% | 0.64% | 0.63% | 0.91% | 0.60% | 0.52% | 0.54% | 1.12% | 0.97% | 1.29% |
UroGen Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. URGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
UroGen Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 5 | 6 | 6 | 3 | 3 | 7 | 4 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | $21.75M | $22.49M | $24.47M | $21.63M | $19.07M | $20.83M | $21.30M | $87.53M | $21.62M | $22.30M | $22.19M | $22.16M | $22.07M | $24.02M | $21.97M | $12.71M | $6.07M |
| Avg Forecast | $34.34B | $27.04B | $21.91B | $15.73B | $19.65B | $16.49B | $16.09B | $14.36B | $15.15B | $13.45B | $13.51B | $11.49B | $12.43B | $13.52B | $11.56B | $22.00 | $10.90B | $10.31B | $7.89B | $6.08B | $5.12B | $2.24B | $265.93M | $607.49K | $67.13M | $251.12M |
| High Forecast | $36.90B | $29.06B | $23.54B | $16.90B | $21.11B | $17.02B | $17.29B | $15.43B | $15.49B | $14.45B | $14.51B | $12.34B | $13.35B | $14.53B | $12.15B | $27.00 | $11.46B | $10.84B | $8.30B | $6.39B | $5.38B | $2.35B | $279.55M | $728.31K | $70.56M | $301.35M |
| Low Forecast | $32.37B | $25.49B | $20.65B | $14.82B | $18.52B | $15.96B | $15.17B | $13.53B | $14.81B | $12.68B | $12.73B | $10.83B | $11.71B | $12.75B | $11.13B | $18.00 | $10.49B | $9.93B | $7.60B | $5.85B | $4.92B | $2.15B | $255.93M | $485.32K | $64.60M | $200.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 968181.82% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% | 0.09% | 36.17% | 0.19% | 0.02% |
UroGen Pharma's average Quarter SG&A projection for Dec 23 is $15.15B, based on 3 Wall Street analysts, with a range of $14.81B to $15.49B. The forecast indicates a 69535.82% rise compared to URGN last annual SG&A of $21.75M (Sep 23).
UroGen Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 5 | 6 | 6 | 3 | 3 | 7 | 4 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.68 | $-1.03 | $-1.30 | $-1.22 | $-1.13 | $-1.18 | $-1.25 | $-1.27 | $-1.35 | $-1.17 | $-1.17 | $-1.38 | $-1.31 | $-1.44 | $-1.79 | $-1.11 | $-0.88 |
| Avg Forecast | $-0.51 | $-0.71 | $-0.81 | $-0.95 | $-0.78 | $-0.83 | $-0.83 | $-0.87 | $-0.68 | $-0.85 | $-1.14 | $-1.33 | $-1.07 | $-1.16 | $-1.27 | $-1.33 | $-1.18 | $-1.28 | $-1.14 | $-1.29 | $-1.37 | $-1.50 | $-1.59 | $-1.62 | $-1.16 | $-0.56 |
| High Forecast | $-0.47 | $-0.65 | $-0.75 | $-0.88 | $-0.72 | $-0.79 | $-0.77 | $-0.80 | $-0.62 | $-0.78 | $-1.05 | $-1.23 | $-0.99 | $-1.07 | $-1.21 | $-1.27 | $-1.12 | $-1.22 | $-1.08 | $-1.23 | $-1.30 | $-1.42 | $-1.51 | $-1.54 | $-1.10 | $-0.45 |
| Low Forecast | $-0.56 | $-0.77 | $-0.89 | $-1.04 | $-0.86 | $-0.90 | $-0.91 | $-0.95 | $-0.71 | $-0.93 | $-1.25 | $-1.46 | $-1.18 | $-1.27 | $-1.36 | $-1.42 | $-1.25 | $-1.37 | $-1.21 | $-1.38 | $-1.46 | $-1.59 | $-1.70 | $-1.72 | $-1.24 | $-0.67 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.80% | 0.91% | 0.98% | 1.14% | 0.98% | 0.93% | 0.94% | 1.08% | 1.05% | 1.03% | 0.90% | 1.01% | 0.88% | 0.91% | 1.11% | 0.96% | 1.57% |
According to undefined Wall Street analysts, UroGen Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to URGN previous annual EPS of $NaN (undefined).
UroGen Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XLO | Xilio Therapeutics | $0.81 | $7.00 | 764.20% | Buy |
| KRON | Kronos Bio | $0.92 | $7.63 | 729.35% | Buy |
| OVID | Ovid Therapeutics | $1.06 | $7.33 | 591.51% | Buy |
| VACC | Barinthus Biotherapeutics | $5.00 | $22.00 | 340.00% | - |
| SRRK | Scholar Rock | $8.27 | $29.50 | 256.71% | Buy |
| URGN | UroGen Pharma | $13.10 | $42.00 | 220.61% | Buy |
| PEPG | PepGen | $9.26 | $29.50 | 218.57% | Buy |
| VIGL | Vigil Neuroscience | $3.47 | $11.00 | 217.00% | Buy |
| CMPX | Compass Therapeutics | $1.63 | $5.00 | 206.75% | Buy |
| PRTC | PureTech Health | $19.42 | $57.00 | 193.51% | Buy |
| EWTX | Edgewise Therapeutics | $19.07 | $48.00 | 151.70% | Buy |
| ERAS | Erasca | $2.89 | $7.00 | 142.21% | Buy |
| CELC | Celcuity | $15.01 | $31.50 | 109.86% | Buy |
| CCCC | C4 Therapeutics | $6.38 | $11.33 | 77.59% | Hold |
| ELYM | Eliem Therapeutics | $7.98 | $13.00 | 62.91% | Buy |
| ELVN | Enliven Therapeutics | $21.76 | $33.00 | 51.65% | Buy |
| CNTB | Connect Biopharma | $1.18 | $1.50 | 27.12% | Buy |
| TYRA | Tyra Biosciences | $23.20 | $25.00 | 7.76% | Buy |
| IKNA | Ikena Oncology | $1.66 | $1.33 | -19.88% | Buy |
URGN Forecast FAQ
Is UroGen Pharma a good buy?
Yes, according to 8 Wall Street analysts, UroGen Pharma (URGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of URGN's total ratings.
What is URGN's price target?
UroGen Pharma (URGN) average price target is $42 with a range of $22 to $60, implying a 220.61% from its last price of $13.1. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will UroGen Pharma stock go up soon?
According to Wall Street analysts' prediction for URGN stock, the company can go up by 220.61% (from the last price of $13.1 to the average price target of $42), up by 358.02% based on the highest stock price target, and up by 67.94% based on the lowest stock price target.
Can UroGen Pharma stock reach $20?
URGN's average twelve months analyst stock price target of $42 supports the claim that UroGen Pharma can reach $20 in the near future.
What are UroGen Pharma's analysts' financial forecasts?
UroGen Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $99.2M (high $105.55M, low $94.12M), average EBITDA is $-94.667M (high $-89.824M, low $-101M), average net income is $-122M (high $-114M, low $-133M), average SG&A $66.59B (high $70.85B, low $63.18B), and average EPS is $-3.307 (high $-3.083, low $-3.616). URGN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $147.51M (high $158.5M, low $139.05M), average EBITDA is $-141M (high $-133M, low $-151M), average net income is $-110M (high $-102M, low $-120M), average SG&A $99.02B (high $106.39B, low $93.34B), and average EPS is $-2.982 (high $-2.759, low $-3.27).
Did the URGN's actual financial results beat the analysts' financial forecasts?
Based on UroGen Pharma's last annual report (Dec 2023), the company's revenue was $82.71M, beating the average analysts forecast of $79.83M by 3.61%. Apple's EBITDA was $-65.536M, missing the average prediction of $-76.188M by -13.98%. The company's net income was $-102M, missing the average estimation of $-147M by -30.44%. Apple's SG&A was $93.27M, missing the average forecast of $53.59B by -99.83%. Lastly, the company's EPS was $-0.0035, missing the average prediction of $-3.992 by -99.91%. In terms of the last quarterly report (Sep 2023), UroGen Pharma's revenue was $20.85M, beating the average analysts' forecast of $20.03M by 4.08%. The company's EBITDA was $-12.179M, missing the average prediction of $-19.12M by -36.30%. UroGen Pharma's net income was $-21.879M, missing the average estimation of $-31.151M by -29.77%. The company's SG&A was $21.76M, missing the average forecast of $13.45B by -99.84%. Lastly, the company's EPS was $-0.68, missing the average prediction of $-0.846 by -19.62%